ISLAND PHARMACEUTICALS (ILA) - Combating Mosquito-Borne Diseases: Island Pharmaceuticals' CEO Dr. David Foster on ISLA101's Potential and Strategic Roadmap

ASX BRIEFS

Ever wondered how we can combat the surge of mosquito-borne diseases like dengue fever and Zika? Our latest podcast episode features an enlightening conversation with Dr. David Foster, CEO of Island Pharmaceuticals, who shares groundbreaking insights about their leading antiviral candidate, ISLA-101. Dr. Foster discusses the alarming rise in dengue cases, even in unexpected regions such as Queensland and parts of the United States, and how ISLA-101 could be a game-changer in both prevention and treatment of these diseases. Tune in to learn about the science behind repurposing existing molecules to fight all four strains of the dengue virus and other mosquito-borne illnesses.
In the second part of our episode, we delve into the strategic roadmap for Island Pharmaceuticals, exploring the commercial potential of ISLA-101 and future pipeline expansions. Dr. Foster details the significant market opportunities, from travel markets to government stockpile programs in Southeast Asia and Latin America. He also shares the company's innovative approach to acquiring new drug candidates and the importance of strategic collaborations, such as those with Monash University and the US Army. Don't miss out on hearing about the exciting milestones expected over the next 12 to 24 months and how Island Pharmaceuticals aims to make a lasting impact on global health.

Chapters

1. ISLAND PHARMACEUTICALS (ILA) - Combating Mosquito-Borne Diseases: Island Pharmaceuticals' CEO Dr. David Foster on ISLA101's Potential and Strategic Roadmap (00:00:00)

2. Developing Antiviral Drug for Infectious Diseases (00:00:02)

3. Commercial Strategy and Pipeline Expansion (00:10:44)